After a year of expanded ADC design innovations, the antibody‑drug conjugate (ADC) field is entering a commercialization inflection with new targets, linkers and payloads reported across translational studies. BioAtla and GATC Health announced a $40 million special purpose vehicle to advance ozuriftamab vedotin (Oz‑V/CAB‑ROR2‑ADC) into a registrational Phase 3 trial for second‑line+ oropharyngeal squamous cell carcinoma, signaling investor appetite to finance late‑stage ADC programs. The pairing of scientific advances and deal financing highlights how selective partnerships and capital structures can accelerate registrational plans for ADC candidates.